The KIWE randomised trial (Lancet Neurol 2023) found no superiority of a classic ketogenic diet over an additional antiseizure medication for seizure frequency in infants (1–24 months) with drug‑resistant epilepsy; tolerability and safety profiles were similar, supporting the diet as a viable treatment option.